Actividades asistenciales
Knee brace hinge mechanism
01/06/2026 -
Przedmiotem zgłoszenia jest mechanizm zawiasowy ortezy stawu kolanowego zbudowany z komponentu udowego i komponentu piszczelowego połączonych zawiasowo za pomocą sworznia, który...
RECOMBINANT EXPRESSION SYSTEMS AND RADIATION USEFUL FOR THE TREATMENT OF CANCER
25/06/2026 -
Recombinant expression systems and radiation useful for the treatment of cancer The invention relates to a recombinant expression system comprising a nucleic acid construct, particularly for use...
S100A1 PROTEIN-DERIVED PEPTIDE FOR USE IN TREATING CANCER OR IN TREATING OR PREVENTING ANTINEOPLASTIC AGENT-MEDIATED CYTOTOXICITY, CANCER THERAPY-RELATED CARDIAC DYSFUNCTION OR CANCER THERAPY RELATED HEART FAILURE
25/06/2026 -
The present invention pertains to a peptide of the S100A1 protein for use in the treatment or prevention of antineoplastic agent-mediated cytotoxicity or cancer therapy-related cardiac dysfunction...
INHIBITORY COMPOUNDS
25/06/2026 -
The present invention relates to certain compounds that function as inhibitors of DHX9 activity (RNA Helicase A / RHA or Nuclear DNA Helicase II / NDH II). The present invention also relates to...
COMBINATION THERAPIES USING CDK4 INHIBITORS WITH PD-1 AXIS BINDING ANTAGONISTS
25/06/2026 -
This invention relates to, in part, a method for treating cancer by administering a CDK4 inhibitor in combination with a PD-1 axis binding antagonist, and optionally an CDK2 inhibitor to a subject...
EGFR INHIBITOR-FUNCTIONALIZED ALBUMIN-BINDING PLATINUM COMPOUNDS FOR CANCER THERAPY
25/06/2026 -
The present invention relates to novel EGFR inhibitor-functionalized albumin-binding platinum compounds of formula (I), including in particular EGFR inhibitor-functionalized albumin-binding...
CD70-TARGETED CARS AND ENGINEERED CELLS COMPRISING SAME AND RELATED METHODS
25/06/2026 -
[0000] Provided herein are CD70-targeted chimeric antigen receptors (CARs), genetically engineered cells such as T cells containing the same, and related methods and uses of the genetically...
KAT6 TARGETING COMPOUNDS
25/06/2026 -
The present disclosure provides bifunctional compounds comprising a target protein binding moiety and a E3 ubiquitin ligase binding moiety, and associated methods of use.
THERAPEUTIC USES OF HER-2 TARGETED BISPECIFIC POLYPEPTIDES
25/06/2026 -
Provided are compositions and methods for treating cancers, in particular those characterized with HER2 expression. The compositions include a conditionally-activatable XTENylated...
MULTISPECIFIC MOLECULES BINDING TRAILR2 AND CDH17 AND USES THEREOF
25/06/2026 -
The present application provides multispecific antigen-binding proteins (e.g., antibodies) that specifically bind TNF-related apoptosis-inducing ligand receptor 2 (TRAILR2) and cadherin 17...
CANCER THERAPY OF SUBJECTS CARRYING MUTATIONS IN A SPLICING FACTOR GENE
25/06/2026 -
The present invention is directed to SEL24/MEN1703 for use in the treatment of a patient suffering from cancer and/or for use in increasing the overall survival of a patient suffering from cancer,...
AXL INHIBITORS FOR THE TREATMENT OF MASTOCYTOSIS
25/06/2026 -
Mastocytosis is a rare and heterogeneous disorder marked by the abnormal accumulation of mast cells (MCs) in various tissues. Tyrosine kinase inhibitors have shown limited efficacy, suggesting...
FUSED AZINES FOR THE TREATMENT OF CANCER
25/06/2026 -
The present invention discloses compounds according to Formula I: [Formula I] I wherein A, B, X1, X2, X3, Y, L1, R1, R2, R3, R4, R5, R6, n, p, and q are as defined herein. The present invention...
COMBINATION OF ANTI-HER2 ANTIBODY-DRUG CONJUGATE AND ANTI-TROP2 ANTIBODY-DRUG CONJUGATE
25/06/2026 -
A pharmaceutical product for administration of an anti- HER2 antibody-drug conjugate (ADC) in combination with an anti-TROP2 ADC is provided. The anti-HER2 ADC and the anti-TROP2 ADC comprise a...
THERAPEUTIC STRATEGY FOR TREATING COPPER-MEDIATED PATHOLOGIES
25/06/2026 -
The present invention is directed to a novel therapeutic strategy for treating a disease mediated by copper, by inhibiting the function of cellular prion protein (PrP).
COMPOSITIONS AND METHODS RELATED TO TUMOR ACTIVATED MOLECULES TARGETING NECTIN-4 AND EFFECTOR CELL ANTIGENS
25/06/2026 -
Disclosed herein are polypeptides and polypeptide complexes that are capable of binding tumor cell antigens and effector cell antigens. In some embodiments, the polypeptides and polypeptide...
ENT1 INHIBITORS IN COMBINATION WITH CAR-T CELL THERAPY
25/06/2026 -
Disclosed herein are combinations, methods, and uses comprising administering an ENT1 inhibitor and a CAR-T cell therapy for the treatment of a disease. In some embodiments, the disease is...
SOLID FORMS COMPRISING AN AMPA POSITIVE ALLOSTERIC MODULATOR
25/06/2026 -
Solid forms comprising 9-(4-(cyclohexyloxy)phenyl)-7-methyl-3,4-dihydropyrazino[2,1-c][1,2,4]thiadiazine 2,2-dioxide (Compound (I)), compositions comprising the same, and methods of making and...
SULFONAMIDE DERIVATIVES USEFUL AS GPR17 MODULATORS
25/06/2026 -
THERAPEUTIC COMPOUNDS The present invention relates to compounds of Formula (I) which act to attenuate or block the function of the GPR17 receptor (e.g. compounds which act as GPR17 antagonists),...
THERAPEUTIC STRATEGY FOR TREATING COPPER-MEDIATED PATHOLOGIES
25/06/2026 -
The present invention is directed to a novel therapeutic strategy for treating a disease mediated by copper, by inhibiting the function of cellular prion protein (PrP).
FUSED AZINES AS KCC2 POTENTIATORS AND USES THEREOF
25/06/2026 -
The present disclosure provides compounds, compositions, and methods for treating or preventing neurological disorders in a patient. The disclosed methods include administration to a subject...
Actividades asistenciales
Agroalimentación
Automoción y nueva movilidad
Energía sostenible y eficiente
Materiales avanzados
Medio ambiente y sostenibilidad
Patrimonio natural y cultural
Procesos productivos e industria 4.0
Química y biotecnología
Salud y calidad de vida
Transformación digital



